Commercialization of microwave thermokeratoplasty
Commercialization of microwave thermokeratoplasty
批准号:
6948453
负责人:
David Muller
金额:
$37.9万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-09-01 至 2008-08-31
关键词:
AcuteAnimalsCaliberCharacteristicsChronicClinicalComplicationCorneaDevicesElevationEndotheliumEpitheliumEquipmentFeedbackGeneral AnesthesiaHealedIn SituLasersLesionLocationMethodsMyopiaOperative Surgical ProceduresOpticsPatternPhasePlacementPopulationPupilSignal TransductionSurfaceSurgeonSystemTemperatureTestingTissuesToxic effectUnited States Food and Drug AdministrationWorkabsorptionbasecommercializationcorneal epitheliumdesign and constructionelectric impedanceeye drynessfollow-uphealingimprovedin vivoin vivo Modelkeratomileusismicrowave electromagnetic radiationnovelresponsetreatment centertreatment duration
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant):
Microwave Thermokeratoplasty (MTK) shrinks the stromal (middle) layer of the cornea in a ring pattern around the pupil in response to elevation of temperature by absorption of microwave energy; the central cornea flattens as a result, thus correcting for myopia. About 50% of the U.S. population requires correction for myopia. This novel method has advantages over the most common surgical treatment for myopia, laser assisted in-situ keratomileusis (LASIK). Specifically, MTK:
Involves no surgical intervention in the central cornea.
Requires no period of healing.
Does not use expensive equipment.
Involves only a single, 2-second treatment.
Spares the corneal epithelium through its cooling system.
Avoids the dry eye complication characteristic of LASIK.
We will improve the existing MTK system by incorporating a feedback system to achieve precise results and an optical centering system to assist placement on the cornea. We will evaluate the redesigned system in ex vivo and in vivo corneas and quantify the improvement in predictability and repeatability of refractive effect. In Phase I, we will perform an in vivo acute study in five subjects. In Phase II, we will perform an in vivo chronic study with a 3- month follow-up period. This work will support our application to the FDA for an Investigational Device Exemption.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金